On ECHEMI
Home > Drugs > Etoposide

Etoposide

Function and Efficacy

Etoposide is an active ingredient of lignans isolated from podophyllin. VP-16 is a cell cycle-specific anti-tumor drug that acts in the late S phase or G2 phase. Its action site is topoisomerase II, forming a stable cleavable complex between drug, enzyme and DNA, interfering with DNA topoisomerase II, rendering the damaged DNA unable to be repaired. Topoisomerase II inserts into DNA to produce the break reaction required for general cell function; VP-16 appears to cause double-line breaks of DNA and topoisomerase II by stabilizing the DNA break complex. This product activates certain endonucleases in vivo, or acts on DNA through its metabolites, and its non-glycoside homologue 4-demethylepipodophyllotoxin can inhibit microtubule assembly.

Ingredients

Chemical name: 4'-demethyl epipodophyllotoxin-beta;-D-ethylidene pyranoglucoside (-)-(5R, 5aR, 8aR, as)-a-[(4,6,-O-CR)-ethylidene-beta;-D-pyranoglucoside]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy, 5-dimethoxyphenyl)furan[3`,4`:6,7]naphtho[2,3-d]-1,3-e9dioxo-6(5aH)-one. Molecular formula: C29H32O13.

Name Description Content CAS NO. Manufacturer
EtoposideIngredients

Etoposide is an effective component of lignans isolated from podophyllin. VP-16 is a cell cycle-specific anti-tumor drug that acts in the late S phase or G2 phase. Its action site is topoisomerase II, forming a stable cleavable complex between drug, enzyme and DNA, interfering with DNA topoisomerase II, making the damaged DNA unable to be repaired. By stabilizing the DNA breakage complex, it causes double-line breaks in DNA and topoisomerase II. It activates certain endonucleases in vivo, or acts on DNA through its metabolites, and its non-glycoside homologue 4-demethylepipodophyllotoxin can inhibit microtubule assembly.

More
33419-42-0 20

Indication

Mainly for small cell lung cancer, the effective rate increased from 40% to 85%, and the complete remission rate was 14% to 34%. For small cell lung cancer, oral administration is more effective than intravenous injection.

Usage and Dosage

Oral administration: Soft capsules, 50 mg each time, 3 times each time, for 5 consecutive days. 21 to 28 days is one cycle, and treatment should be continued for at least 2 cycles.

Adverse Reactions

1. Bone marrow suppression: leukopenia and thrombocytopenia, anemia, which is the dose-limiting toxicity. 2. Gastrointestinal reactions: nausea, vomiting, loss of appetite, stomatitis, diarrhea; occasionally abdominal pain, constipation. 3. Allergic reactions: sometimes allergic reactions such as rash, erythema, itching, etc. may occur. 4. Skin reactions: hair loss is more obvious, sometimes even complete baldness, but it is reversible. 5. Socio-economic toxicity: numbness of hands and feet, headache, etc. 6. Other reactions: fever, abnormal electrocardiogram, hypotension, phlebitis, etc.

Precautions

1. Patients with severe bone marrow suppression and patients with a history of severe allergic reaction to this product are contraindicated. 2. Patients with liver and kidney damage and concurrent infection, and patients with varicella should use this product with caution.

Drug Interactions

Not yet clear.

Storage

Keep away from light and store in a sealed container.

Manufacturer

Wichita, Its Group of Pharmaceutical Co., Ltd.

  • Founded in:

    2002-09-30
  • Address:

    Datong Economic and Technological Development Zone, Pharmaceutical Industrial Park, High-tech Industrial Park
  • Tax NO.:

    91140200734026330J
  • Registered Funds:

    1120.37123441 million yuan
  • Website:

  • Email:

Other Drugs of Wichita, Its Group of Pharmaceutical Co., Ltd.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.